The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- 16 Nov 2015 Planned primary completion date changed from 1 Sep 2025 to 1 Nov 2025 as reported by ClinicalTrials.gov record.
- 16 Nov 2015 Planned End Date changed from 1 Sep 2027 to 1 Dec 2027 as reported by ClinicalTrials.gov record.
- 16 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.